NCT05665075

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Clinical Study on the Safety and Efficacy of QN-023a Targeting CD33 in Acute Myeloid Leukemia

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML). The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 19 patients will be enrolled.

Conditions

• AML, Adult

Interventions

Type	Name	Description
DRUG	QN-023a	NK cell therapy
DRUG	Cyclophosphamid	Lympho-conditioning Agent
DRUG	Fludarabine	Lympho-conditioning Agent
DRUG	Cytarabine	Lympho-conditioning Agent
DRUG	VP-16	Lympho-conditioning Agent

Timeline

• Start date: 2022-12-24
• Primary completion: 2023-12-24
• Completion: 2025-12-24
• First posted: 2022-12-27
• Last updated: 2023-01-03

Locations

1 site across 1 country: China